Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness
Not Applicable
Recruiting
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000005847
- Lead Sponsor
- Kyoto university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients unsuitable for Sorafenib Allergic reaction to Sorafenib, Pregnant women, Poor renal function(required hemodialysis), Past history of thromboembolism or ischemic heart disease Poor control of hypertension 2.Severe vascular invasion(Vp3,4)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method time to progression, time to treatment failure, overall survival, response rate, disease control rate, safety